Active substances
Ethinylestradiol + Norethisterone
- US FDA 164
- Health Canada 10
- US price lines 14
- NHS prices 2
- WHO EML 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| TRI-NORINYL 28-DAY | 0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG | tablet · oral-28 | DR REDDYS LABS SA | Prescription | 11 Apr 1984 |
| NORETHINDRONE AND ETHINYL ESTRADIOL | 0.035MG;1MG | tablet · oral-28 | WATSON LABS TEVA | Prescription | 29 Jan 1987 |
| NORETHINDRONE AND ETHINYL ESTRADIOL (10/11) | 0.035MG,0.035MG;0.5MG,1MG | tablet · oral-28 | WATSON LABS TEVA | Prescription | 1 Apr 1988 |
| NORTREL 1/35-21 | 0.035MG;1MG | tablet · oral-21 | BARR | Prescription | 28 Feb 1992 |
| NORTREL 0.5/35-28 | 0.035MG;0.5MG | tablet · oral-28 | BARR LABS | Prescription | 28 Feb 1992 |
| NORTREL 1/35-28 | 0.035MG;1MG | tablet · oral-28 | BARR LABS | Prescription | 28 Feb 1992 |
| FEMHRT | 0.005MG;1MG | tablet · oral | WARNER CHILCOTT | Prescription | 15 Oct 1999 |
| NORTREL 7/7/7 | 0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG | tablet · oral-21 | BARR | Prescription | 30 Aug 2002 |
| NORTREL 7/7/7 | 0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG | tablet · oral-28 | BARR | Prescription | 30 Aug 2002 |
| JUNEL 1/20 | 0.02MG;1MG | tablet · oral-21 | BARR LABS | Prescription | 30 May 2003 |
| JUNEL 1.5/30 | 0.03MG;1.5MG | tablet · oral-21 | BARR | Prescription | 30 May 2003 |
| JUNEL FE 1.5/30 | 0.03MG;1.5MG | tablet · oral-28 | BARR | Prescription | 18 Sep 2003 |
| JUNEL FE 1/20 | 0.02MG;1MG | tablet · oral-28 | BARR | Prescription | 18 Sep 2003 |
| BALZIVA-28 | 0.035MG;0.4MG | tablet · oral-28 | BARR | Prescription | 22 Apr 2004 |
| ARANELLE | 0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG | tablet · oral-28 | BARR | Prescription | 29 Sep 2004 |
| TRI-LEGEST FE | 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG | tablet · oral-28 | BARR | Prescription | 26 Oct 2007 |
| NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL | 0.005MG;1MG | tablet · oral | BARR LABS INC | Prescription | 6 Nov 2009 |
| NORETHINDRONE AND ETHINYL ESTRADIOL | 0.035MG;0.4MG | tablet · oral-28 | WATSON LABS | Prescription | 4 Feb 2010 |
| NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE | 0.035MG;0.4MG | tablet · oral | BARR | Prescription | 5 Aug 2010 |
| LO LOESTRIN FE | 0.01MG,0.01MG;1MG,N/A | tablet · oral | APIL | Prescription | 21 Oct 2010 |
| BRIELLYN | 0.035MG;0.4MG | tablet · oral-28 | GLENMARK PHARMS LTD | Prescription | 22 Mar 2011 |
| NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE | 0.035MG;0.4MG | tablet · oral | AMNEAL PHARMS | Prescription | 26 Sep 2011 |
| DASETTA 7/7/7 | 0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG | tablet · oral-28 | NOVAST LABS LTD | Prescription | 22 Dec 2011 |
| PHILITH | 0.035MG;0.4MG | tablet · oral-28 | NOVAST LABS LTD | Prescription | 22 Dec 2011 |
| DASETTA 1/35 | 0.035MG;1MG | tablet · oral-28 | NOVAST LABS LTD | Prescription | 22 Dec 2011 |
139 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| BREVICON 0.5/35 TABLETS (21-DAY PACK) | 02187086 | 0.035 MG; 0.5 MG | TABLET · ORAL | PFIZER CANADA ULC |
| BREVICON 0.5/35 TABLETS (28-DAY PACK) | 02187094 | .5 MG; .035 MG | TABLET · ORAL | PFIZER CANADA ULC |
| BREVICON 1/35 TABLETS (21-DAY PACK) | 02189054 | 1 MG; 0.035 MG | TABLET · ORAL | PFIZER CANADA ULC |
| BREVICON 1/35 TABLETS (28-DAY PACK) | 02189062 | 0.035 MG; 1 MG | TABLET · ORAL | PFIZER CANADA ULC |
| ELFY | 02553481 | 1 MG; 10 MCG | TABLET · ORAL | APOTEX INC |
| LOLO | 02417456 | 10 MCG; 1 MG | TABLET · ORAL | ABBVIE CORPORATION |
| SELECT 1/35 (21-DAY) | 02197502 | 0.035 MG; 1.0 MG | TABLET · ORAL | PFIZER CANADA ULC |
| SELECT 1/35 (28-DAY) | 02199297 | 0.035 MG; 1.0 MG | TABLET · ORAL | PFIZER CANADA ULC |
| SYNPHASIC 21 TABLETS | 02187108 | 0.035 MG; 1.0 MG; 0.5 MG | TABLET · ORAL | PFIZER CANADA ULC |
| SYNPHASIC 28 TABLETS | 02187116 | 0.035 MG; 1.0 MG; 0.5 MG | TABLET · ORAL | PFIZER CANADA ULC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | ARANELLE 28 TABLET | $0.63013 | per EA | 23 Sep 2026 |
| US NADAC | BRIELLYN 0.4 MG-0.035 MG TAB | $0.32955 | per EA | 23 Sep 2026 |
| US NADAC | FEMLYV 1 MG-0.02 MG ODT | $7.04096 | per EA | 1 Sep 2026 |
| US NADAC | FINZALA 1-0.02(24)-75 CHEW TAB | $0.3041 | per EA | 23 Sep 2026 |
| US NADAC | FYAVOLV 0.5 MG-2.5 MCG TABLET | $0.9127 | per EA | 23 Sep 2026 |
| US NADAC | FYAVOLV 1 MG-5 MCG TABLET | $0.57994 | per EA | 23 Sep 2026 |
| US NADAC | GEMMILY 1 MG-20 MCG CAPSULE | $0.96176 | per EA | 23 Sep 2026 |
| US NADAC | KAITLIB FE 0.8-0.025 MG CHEW TB | $1.40353 | per EA | 23 Sep 2026 |
| US NADAC | LO LOESTRIN FE 1-10 TABLET | $6.76607 | per EA | 23 Sep 2026 |
| US NADAC | PHILITH 0.4-0.035 MG TABLET | $0.32955 | per EA | 23 Sep 2026 |
| US NADAC | TAYTULLA 1 MG-20 MCG CAPSULE | $8.97473 | per EA | 23 Sep 2026 |
| US NADAC | TRI-LEGEST FE-28 DAY TABLET | $0.7459 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Ethinylestradiol 35microgram / Norethisterone 1mg tablets | £2.28 | 63 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Ethinylestradiol 35microgram / Norethisterone 500microgram tablets | £1.99 | 63 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 22.1.1. Oral hormonal contraceptives · core
Contact with health services for contraceptive management
Oral > Solid: 35 µg + 1 mg
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.